Q Line Biotech Limited
Minimum investment
Bidding date
21 May - 25 May 2026
Price range
₹326 - ₹343
Minimum quantity
800
Minimum investment
₹1,30,400
Issue size
₹214 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Total Issue Size:
₹214.48 Crore
Fresh Issue: 100% (₹214.48 Cr)
OFS: 0% (₹0 Cr)
Fresh Issue – ₹214.48 Crore
Offer for Sale – ₹0 Crore
Before Issue: 96.77%
After Issue: 70.83%
Lock-in / Stabilization | Timeline |
|---|---|
Promoter Shareholding (Minimum 20% Post Issue Capital) | Locked-in for 3 years from the date of allotment |
Remaining Pre-Issue Promoter Shareholding | Locked-in for 1 year from the date of allotment |
Anchor Investor Portion | 50% locked-in for 90 days and remaining 50% for 30 days from allotment |
Pre-IPO Placement Shares | Locked-in for 1 year from the date of allotment |
Note: Retail IPO investors have no lock-in and can sell shares from the listing day.
Category | Subscription |
|---|---|
Qualified Institutional Buyers | 123.94x |
Retail Individual Investor | 71.44x |
Non-Institutional Investor | 146.32x |
Others | 0.37x |
Total | 95.31x |
Q-Line Biotech Ltd. was incorporated in 2010 and is engaged in the development, manufacturing, and marketing of diagnostic reagents, kits, point-of-care (POC) devices, consumables, and diagnostic equipment. The company also imports and distributes in-vitro diagnostic (IVD) and pathology equipment catering to hospitals, diagnostic laboratories, and medical colleges across India. The company has been supplying diagnostic equipment and IVD products since 2013 through both direct sales and a wide distributor network spread across all four regions of India. Its product portfolio includes Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, Rapid Tests, and POC Devices. As of December 31, 2025, Q-Line Biotech had an annual manufacturing capacity of nearly 1.4 million diagnostic kits and around 1,200 Selectra Machines. The company also has a dedicated manufacturing and R&D team comprising 126 employees along with 223 third-party workers. The company focuses on indigenous manufacturing, reverse engineering capabilities, quality control, and continuous research & development to strengthen its position in the Indian diagnostics industry.
Established Presence in Diagnostic Industry: Q-Line Biotech Ltd. has built a strong presence in the diagnostic healthcare and IVD industry by supplying diagnostic equipment, reagents, and consumables to hospitals, laboratories, and medical colleges across India.
Strong Manufacturing & R&D Capabilities: The company has developed in-house manufacturing capabilities supported by research & development and reverse engineering expertise. Its production capacity includes nearly 1.4 million diagnostic kits and around 1,200 Selectra Machines annually.
Diversified Product Portfolio: Q-Line Biotech offers products across multiple diagnostic segments including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, Rapid Tests, and POC Devices, reducing dependency on a single product category.
Wide Distribution Network: The company has established a pan-India distribution network covering all four regions of India, helping it expand its customer base and strengthen market reach.
Long-Term Customer Relationships: Q-Line Biotech has developed long-standing relationships with diagnostic service providers, hospitals, and medical institutions, which supports recurring business opportunities.
Industry Dependency Risk: The company’s business performance is highly dependent on the healthcare and diagnostics industry. Any slowdown in this sector may impact demand for its products.
Rising Borrowings: Q-Line Biotech has significant borrowings on its balance sheet, and higher debt levels could impact profitability and cash flows in the future.
Intense Competition: The diagnostic and IVD industry is highly competitive with the presence of established domestic and multinational companies, which may affect market share and pricing power.
Regulatory Risk: The healthcare and medical diagnostics sector is subject to strict regulations. Any adverse regulatory changes could impact operations and product approvals.
Working Capital Intensive Business: The company requires substantial working capital to manage inventory, manufacturing, and distribution operations, which may increase funding requirements.
236.5 Cr.
Dec'25
38.69 Cr.
Dec'25
64.23 Cr.
Dec'25
57 investors voted
Active IPOs | |
|---|---|
Company name | Bid starts |
Hexagon Nutrition | 05-06-2026 |
Genxai Analytics | 05-06-2026 |
